2021
DOI: 10.1007/s11302-021-09823-5
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
38
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 8 publications
(40 citation statements)
references
References 38 publications
2
38
0
Order By: Relevance
“…In fact, the EC 50 of Cl-IB-MECA in the presence of 10 μM compound 4 was significantly reduced 5-fold from 10.5 to 2.24 nM ( p < 0.05), while in assays with the wild-type hA 3 AR the EC 50 was increased 5-fold by 10 μM compound 4 (15.1 vs 72.5 nM; p < 0.05). Because the binding affinity of non-nucleoside typical non-nucleoside hA 3 AR antagonist ligands in the mA 3 AR is greatly reduced as compared to the hA 3 AR, we predicted that the enhanced potency of Cl-IB-MECA observed with the M Out /H In chimera is explained by reduced affinity of compound 4 for the orthosteric binding site composed of the mouse sequence. To further test this idea, we examined the 2-cyclopropyl imidazoquinolin-4-amine derivative ( 1 ) in [ 35 S]­GTPγS binding assays with human/mouse chimeric receptors, which lacks efficacy-enhancing allosteric activity but greatly right-shifts the Cl-IB-MECA concentration–response relationship in assays with the hA 3 AR in a manner suggestive of competitive antagonism.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…In fact, the EC 50 of Cl-IB-MECA in the presence of 10 μM compound 4 was significantly reduced 5-fold from 10.5 to 2.24 nM ( p < 0.05), while in assays with the wild-type hA 3 AR the EC 50 was increased 5-fold by 10 μM compound 4 (15.1 vs 72.5 nM; p < 0.05). Because the binding affinity of non-nucleoside typical non-nucleoside hA 3 AR antagonist ligands in the mA 3 AR is greatly reduced as compared to the hA 3 AR, we predicted that the enhanced potency of Cl-IB-MECA observed with the M Out /H In chimera is explained by reduced affinity of compound 4 for the orthosteric binding site composed of the mouse sequence. To further test this idea, we examined the 2-cyclopropyl imidazoquinolin-4-amine derivative ( 1 ) in [ 35 S]­GTPγS binding assays with human/mouse chimeric receptors, which lacks efficacy-enhancing allosteric activity but greatly right-shifts the Cl-IB-MECA concentration–response relationship in assays with the hA 3 AR in a manner suggestive of competitive antagonism.…”
Section: Resultsmentioning
confidence: 99%
“…For other S1 and S2. We next evaluated the two series of modulators in a [ 35 S]GTPγS binding assay using isolated HEK293 cell membranes expressing the hA 3 AR, which detects receptorinduced G protein activation. For these studies, concen- S3.…”
Section: Pharmacological Characterization Of Novel a 3 Armentioning
confidence: 99%
See 1 more Smart Citation
“… 18 Experiments showed that the other A3R antagonist VUF5574 was responsible for neuroprotective and anti-inflammatory effects and was suitable for potential treatment of glaucoma and asthma. 19 …”
Section: Introductionmentioning
confidence: 99%
“…18 Experiments showed that the other A3R antagonist VUF5574 was responsible for neuroprotective and antiinflammatory effects and was suitable for potential treatment of glaucoma and asthma. 19 Most previous studies have examined the effects of ADO, whereas the role of AR antagonists has been evaluated alone, and there is a lack of data on what transpires in real-world environments where adenosine exerts its protective effects in response to injury. In this study, we applied PC12 (rat adrenal pheochromocytoma) cells to imitate neuronal cells and test whether antagonists might adjust the PC12 cell injury induced by paraquat in the presence or absence of adenosine pretreatment.…”
Section: Introductionmentioning
confidence: 99%